Peritoneal morphology after long-term peritoneal dialysis with biocompatible fluid: Recent clinical practice in Japan

Peritoneal Dialysis International

Volumn 32, Issue 2, 2012, Pages 159-167

  Ayuzawa, Nobuhiro ^a   Ishibashi, Yoshitaka ^a   Takazawa, Yutaka ^a   Kume, Haruki ^a   Fujita, Toshiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Peritoneal membrane morphology; Peritoneal solute transport

Indexed keywords

CREATININE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; DIALYSATE; DISEASE COURSE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYALINIZING VASCULOPATHY; JAPAN; KIDNEY FAILURE; LONG TERM CARE; MALE; PERITONEAL BIOPSY; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; PERITONEAL INTERSTITIAL SCLEROSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; VASCULAR DISEASE; VENULE;

ADULT; AGED; DIALYSIS SOLUTIONS; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; PERITONEUM; TIME FACTORS;

EID: 84857893776     PISSN: 08968608     EISSN: 17184304     Source Type: Journal    
DOI: 10.3747/pdi.2010.00234     Document Type: Article

References (39)

1. Churchill DN, Thorpe KE, Nolph KD, Keshaviah PR, Oreo-poulos DG, Pagé D. Increased peritoneal membrane transport is associated with decreased patient and technique survival for continuous peritoneal dialysis patients. The Canada-USA (CANUSA) Peritoneal Dialysis Study Group. J am Soc Nephrol 1998; 9:1285-1292.
2. Davies SJ, Bryan J, Phillips L, Russell GI. Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant 1996; 11:498-506.
3. Davies SJ, Phillips L, Griffiths AM, Russell LH, Naish PF, Russell GI. What really happens to people on long-term peritoneal dialysis? Kidney Int 1998; 54:2207-2217.
4. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, et al. On behalf of the Peritoneal Biopsy Study Group. Morphologic changes in the peritoneal membrane of patients with renal disease. J am Soc Nephrol 2002; 13:470-479.
5. Honda K, Hamada C, Nakayama M, Miyazaki M, Sherif AM, Harada T, et al. On behalf of the Peritoneal Biopsy Study Group of the Japanese Society for Peritoneal Dialysis. Impact of uremia, diabetes, and peritoneal dialysis itself on the pathogenesis of peritoneal sclerosis: a quantitative study of peritoneal membrane morphology. Clin J am Soc Nephrol 2008; 3:720-728.
6. Margetts PJ, Bonniaud P. Basic mechanisms and clinical implications of peritoneal fibrosis. Perit Dial Int 2003; 23:530-541.
7. Davies SJ, Phillips L, Naish PF, Russell GI. Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J am Soc Nephrol 2001; 12:1046-1051.
8. Hendriks PM, Ho-dac-Pannekeet MM, van Gulik TM, Struijk DG, Phoa SS, Sie L, et al. Peritoneal sclerosis in chronic peritoneal dialysis patients: analysis of clinical presentation, risk factors, and peritoneal transport kinetics. Perit Dial Int 1997; 17:136-143.
9. Selgas R, Fernandez-Reyes MJ, Bosque E, Bajo MA, Bor-rego F, Jimenez C, et al. Functional longevity of the human peritoneum: how long is continuous peritoneal dialysis possible? Results of a prospective medium long-term study. am J Kidney Dis 1994; 23:64-73.
10. Williams JD, Topley N, Craig KJ, Mackenzie RK, Pisch-etsrieder M, Lage C, et al. On behalf of the Euro Balance Trial Group. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (Balance) on the peritoneal membrane. Kidney Int 2004; 66:408-418.
11. Kim S, Oh J, Kim S, Chung W, Ahn C, Kim SG, et al. Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study. Nephrol Dial Transplant 2009; 24:2899-2908.
12. Kawanishi H, Hashimoto Y, Nakamoto H, Nakayama M, Tranæus A. Combination therapy with peritoneal dialysis and hemodialysis. Perit Dial Int 2006; 26:150-154.
13. Working Group Committee for Preparation of Guidelines for Peritoneal Dialysis, Japanese Society for Dialysis Therapy; Japanese Society for Dialysis Therapy. 2009 Japanese Society for Dialysis Therapy guidelines for peritoneal dialysis. Ther apher Dial 2010; 14:489-504.
14. Jörres A, Bender TO, Finn A, Witowski J, Fröhlich S, Gahl GM, et al. Biocompatibility and buffers: effect of bicarbonate-buffered peritoneal dialysis fluids on peritoneal cell function. Kidney Int 1998; 54:2184-2193.
15. Flessner MF, Credit K, Henderson K, Vanpelt HM, Potter R, He Z, et al. Peritoneal changes after exposure to sterile solutions by catheter. J am Soc Nephrol 2007; 18:2294-2302.
16. Zareie M, Keuning ED, ter Wee PM, Schalkwijk CG, Beelen RH, van den Born J. Improved biocompatibility of bicar-bonate/lactate-buffered PDF is not related to pH. Nephrol Dial Transplant 2006; 21:208-216.
17. Zareie M, Hekking LH, Welten AG, Driesprong BA, Schadee-Eestermans IL, Faict D, et al. Contribution of lactate buffer, glucose and glucose degradation products to peritoneal injury in vivo. Nephrol Dial Transplant 2003; 18:2629-2637.
18. Chan TM, Yung S. Studying the effects of new peritoneal dialysis solutions on the peritoneum. Perit Dial Int 2007; 27(Suppl 2):S87-S93.
19. Mortier S, Faict D, Lameire NH, De Vriese AS. Benefits of switching from a conventional to a low-GDP bicarbonate/ lactate-buffered dialysis solution in a rat model. Kidney Int 2005; 67:1559-1565.
20. Musi B, Braide M, Carlsson O, Wieslander A, Albrektsson A, Ketteler M, et al. Biocompatibility of peritoneal dialysis fluids: long-term exposure of nonuremic rats. Perit Dial Int 2004; 24:37-47.
21. Wieczorowska Tobis K, Polubinska A, Schaub TP, Schilling H, Wisniewska J, Witowski J, et al. Influence of neutral-pH dialysis solutions on the peritoneal membrane: a long-term investigation in rats. Perit Dial Int 2001; 21(Suppl 3):S108-S113.
22. Honda K, Nitta K, Horita S, Yumura W, Nihei H, Nagai R, et al. Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration. Nephrol Dial Transplant 1999; 14:1541-1549.
23. Morgan LW, Wieslander A, Davies M, Horiuchi T, Ohta Y, Beavis MJ, et al. Glucose degradation products (GDP) retard remesothelialization independently of d-glucose concentration. Kidney Int 2003; 64:1854-1866.
24. Mortier S, Faict D, Schalkwijk CG, Lameire NH, De Vriese AS. Long-term exposure to new peritoneal dialysis solutions: effects on the peritoneal membrane. Kidney Int 2004; 66:1257-1265.
25. Schwenger V, Morath C, Salava A, Amann K, Seregin Y, Deppisch R, et al. Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced glycation end-products. J am Soc Nephrol 2006; 17:199-207.
26. Tauer A, Knerr T, Niwa T, Schaub TP, Lage C, Passlick-Deetjen J, et al. In vitro formation of Nε-(carboxymethyl) lysine and imidazolones under conditions similar to continuous ambulatory peritoneal dialysis. Biochem Biophys Res Commun 2001; 280:1408-1414.
27. Tauer A, Zhang X, Schaub TP, Zimmeck T, Niwa T, Passlick-Deetjen J, et al. Formation of advanced glycation end products during CAPD. am J Kidney Dis 2003; 41(Suppl 1):S57-S60.
28. Zeier M, Schwenger V, Deppisch R, Haug U, Weigel K, Bahner U, et al. Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation? Kidney Int 2003; 63:298-305.
29. Hekking LH, Zareie M, Driesprong BA, Faict D, Welten AG, de Greeuw I, et al. Better preservation of peritoneal morphologic features and defense in rats after long-term exposure to a bicarbonate/lactate-buffered solution. J am Soc Nephrol 2001; 12:2775-2786.
30. Kim CD, Kwon HM, Park SH, Oh EJ, Kim MH, Choi SY, et al. Effects of low glucose degradation products peritoneal dialysis fluid on the peritoneal fibrosis and vascular-ization in a chronic rat model. Ther apher Dial 2007; 11:56-64.
31. Lee EA, Oh JH, Lee HA, Kim SI, Park EW, Park KB, et al. Structural and functional alterations of the peritoneum after prolonged exposure to dialysis solutions: role of aminoguanidine. Perit Dial Int 2001; 21:245-253.
32. Zareie M, Tangelder GJ, ter Wee PM, Hekking LH, van Lambalgen AA, Keuning ED, et al. Beneficial effects of aminoguanidine on peritoneal microcirculation and tissue remodelling in a rat model of PD. Nephrol Dial Transplant 2005; 20:2783-2792.
33. Lee HY, Park HC, Seo BJ, Do JY, Yun SR, Song HY, et al. Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degrada- tion product concentration (Balance). Perit Dial Int 2005; 25:248-255.
34. Fan SL, Pile T, Punzalan S, Raftery MJ, Yaqoob MM. Randomized controlled study of biocompatible peritoneal dialysis solutions: effect on residual renal function. Kidney Int 2008; 73:200-206.
35. Lo WK, Bargman JM, Burkart J, Krediet RT, Pollock C, Kawanishi H, et al. On behalf of the ISPD Adequacy of Peritoneal Dialysis Working Group. Guideline on targets for solute and fluid removal in adult patients on chronic peritoneal dialysis. Perit Dial Int 2006; 26:520-522.
36. Rippe B, Simonsen O, Heimbürger O, Christensson A, Haraldsson B, Stelin G, et al. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 2001; 59:348-357.
37. Rippe B, Wieslander A, Musi B. Long-term results with low glucose degradation product content in peritoneal dialysis fluids. Contrib Nephrol 2003; (140):47-55.
38. Choi HY, Kim DK, Lee TH, Moon SJ, Han SH, Lee JE, et al. The clinical usefulness of peritoneal dialysis fluids with neutral pH and low glucose degradation product concentration: an open randomized prospective trial. Perit Dial Int 2008; 28:174-182.
39. Davies SJ. Longitudinal relationship between solute transport and ultrafiltration capacity in peritoneal dialysis patients. Kidney Int 2004; 66:2437-2445.